KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory (2016 - 2025)

Historic Inventory for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $185.8 million.

  • Halozyme Therapeutics' Inventory rose 4138.43% to $185.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.8 million, marking a year-over-year increase of 4138.43%. This contributed to the annual value of $141.9 million for FY2024, which is 1117.47% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Inventory stood at $185.8 million for Q3 2025, which was up 4138.43% from $181.5 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Inventory registered a high of $185.8 million during Q3 2025, and its lowest value of $47.8 million during Q1 2022.
  • Its 5-year average for Inventory is $116.1 million, with a median of $127.6 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Inventory tumbled by 1813.76% in 2022, and later skyrocketed by 12512.3% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Inventory stood at $53.9 million in 2021, then soared by 85.73% to $100.1 million in 2022, then grew by 27.44% to $127.6 million in 2023, then grew by 11.17% to $141.9 million in 2024, then surged by 30.97% to $185.8 million in 2025.
  • Its Inventory stands at $185.8 million for Q3 2025, versus $181.5 million for Q2 2025 and $164.9 million for Q1 2025.